Actively Recruiting
Randomized Phase 2 Study Evaluating NT-101 Eye Drops for Wet Age-Related Macular Degeneration
Led by NexThera Co., Ltd. · Updated on 2026-09-16
66
Participants Needed
3
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of NT-101, a topical eye drop solution, in treating patients with wet age-related macular degeneration AMD. This phase 2 study is randomized, double-blind, placebo-controlled, and conducted at multiple centers. It aims to compare the effects of NT-101 versus placebo on vision and eye health over a 12-week treatment period. Participants will be randomly assigned to receive either NT-101 ophthalmic solution or a placebo, both administered as two drops into the affected eye twice daily for 12 weeks. The study includes a 4-week screening phase, followed by treatment, and a 4-week follow-up after treatment ends. Visits for assessments occur at baseline, Weeks 4, 8, and 12, with an additional visit if participants discontinue early. Throughout the study, participants will undergo various eye examinations such as best corrected visual acuity BCVA, slit-lamp exams, intraocular pressure measurements, optical coherence tomography OCT, and retinal imaging including fluorescein angiography. Safety is monitored by recording adverse events at each visit. The main outcome measured is the change in visual acuity at Week 12 compared to before treatment, with secondary measures including eye structure changes and safety up to Week 16.
CONDITIONS
Brief Title
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
Research Team
Y
Youngwoon Kong, Bachelor's degree
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here